major new issu full print
overal full result consist
pre-announce good news major new issu
disclos detail pleas see patienc test
miss reset specif report revenu vs
estim pre-announc though still initi
estim result impli growth y/i vs forecast
guidanc y/i provid addit detail three factor
attribut revenu miss clear new
forecast take much conserv view time implement
popul sequenc initi notabl attribut delay
lower outlook addit time need parti put place piec
groundwork sever initi overal delay disappoint
chang enthusiasm around multi-year opportun addit
compani forecast assum much weaker outlook dtc test think
de-risk near term outlook final weaker
perform appear transitori given strong nextseq placement quarter
importantli none issu reduc convict novaseq upgrad
cycl adjust order delay note novaseq shipment came
expect addit novaseq consum line forecast
turn guid reiter revenu outlook
pre-announc compani formal lower ep guidanc
also came revis forecast
overal think found good balanc protect invest
busi well provid downsid relief investor believ
illumina guidanc appropri conserv
disappoint print remain confid overal sequenc outlook
reiter ow rate pt
quarterli annual ep usd
return equiti ttm
link barclay live interact chart
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
overweight leader next
gener sequenc project
signific growth driven larg research studi
nascent opportun clinic diagnost
signific competit moat rel
competit given brand scale
growth forseeabl futur
compani instal base grow higher
consum revenu contribut margin
leverag estim upsid case
reflect upsid ep
growth ultim depend
custom fund includ govern grant
nih well clinic reimburs lower
downsid case reflect downsid
ep
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
result consist
pre-announce good news major new issu disclos
detail pleas see patienc test miss
reset specif report revenu vs estim
pre-announc though still initi estim
result impli growth y/i vs forecast guidanc y/i illumina
provid addit detail three factor attribut
revenu miss clear new forecast take much
conserv view time implement popul sequenc
initi notabl attribut delay lower outlook addit
time need parti put place piec groundwork sever initi overal
delay disappoint chang enthusiasm around multi-year
opportun addit compani forecast assum much weaker outlook
direct -to-consum dtc test think de-risk near term outlook final
placement quarter importantli none issu reduc convict
novaseq upgrad cycl adjust order delay note
novaseq shipment came ahead expect addit novaseq consum
quarter line origin forecast
turn guid reiter revenu outlook
pre-announc compani formal lower ep guidanc
also came revis forecast overal
think found good balanc protect invest busi well
provid downsid relief investor believ illumina guidanc
appropri conserv disappoint print remain confid
overal sequenc outlook reiter ow rate pt
report earn roughli line preliminari result juli
specif report revenu
estim time report result impli growth y/i vs
origin forecast guidanc y/i attribut revenu
miss sever factor
popul sequenc roughli versu compani intern forecast
revenu popul sequenc initi came lower impact
sizabl system consum order slip origin expect
second half june given heighten time uncertainti project
manag decid take cautiou stanc contribut compani
assum modest contribut popul sequenc us
nh clinic volum expect contribut start
 direct-to-consum dtc market attribut
miss on-going weak direct-to-consum dtc market primarili
impact compani array busi compani previous cautiou
around dtc market embed lsd growth declin believ
updat impli market deterior due weak market
compani forecast declin array revenu
 nextseq under-perform instrument line grew q/q y/i
revenu fell short expect compani nextseq
pull-through line recent rais guidanc rang said
miseq util came guidanc rang quarter
pinpoint specif driver outsiz impact quarter
note overal revenu due program factor fell short expect
compani full result reiter guidanc issu
compani pre-announce juli pre-announce reset
expect project revenu growth approxim
previou guidanc revenu reset attribut
conserv outlook dtc ramp popul genom well lower
non-high-throughput sequenc system consum embed guidanc
growth sequenc revenu includ sequenc consum growth
slight y/i declin sequenc servic previous guid mid-
teen sequenc revenu sequenc consum growth given dtc
test weak array revenu anticip declin y/i roughli
flat april guidanc posit novaseq pull-through still expect higher
shipment platform expect flat slightli y/i
line previou guidanc
ep expect rang
previous repres growth keep mind pacbio
expect close end includ dilut estim
gross margin expect y/i opex percentag
revenu forecast improv y/i guidanc also assum flat tax rate y/i
non-controlling interest expens helix due deconsolid share
count
revenu forecast grow y/i roughli gross margin
expect slightli versu due mix oper expens expect
improv percentag revenu sequenti basi due
compani opex effici initi compani tax rate forecast
guidanc growth gross op base per sharenon-gaap interest extinguish debtleg contingenciescost-method investmentsconting compensationheadquart slightli slightli barclay illumina inc
neg guidanc revis surpris compani consist
track record execut look back beaten initi revenu
forecast year ep forecast year averag revenu upsid around
translat ep upsid versu initi guidanc addit year
revenu outperform initi guidanc averag beat revenu
ep
track record actual result vs initi guidanc
note adj ep current forecast revenu actual provid present
adjust delay popul sequenc order note
novaseq shipment would exceed expect quarter
comment novaseq order hiseq user addit
order desktop sequenc new-to-sequenc custom prove
novaseq expand market sequenc compani still believ
novaseq upgrad cycl span multipl year approxim
high throughput custom begun transit novaseq
expect closer hiseq custom transit novaseq end
drive adopt broader rang custom announc sever
chang lower-throughput flow cell strategi novaseq compani decreas
price flow cell respect combin
launch prime sp flow cell compani hope catalyz placement
lower throughput hiseq custom sp shipment doubl q/q follow
launch growth flow cell off-set price declin
model estim place novaseq placement
averag consum pull-through follow expect
placement assum novaseq
place repres replac least one hiseq compani start see
cannib hiseq custom well given rel advantag novaseq
forecast billion novaseq revenu year launch
compar million nextseq revenu million hiseq revenu
year launch assumpt model place
novaseq per year hiseq hiseq decommiss persist beyond given multi-
year adopt util increas per novaseq end
model million survey averag sinc assum new custom add
lower overal average
barclay research revenu build
pleas see survey
say elast
upgrad ow
remind survey march-april show signific
demand novaseq continu expect major custom transit toward
platform custom spoke broadli expect de-commiss
hiseq hiseq instal base novaseq addit replac least
instrument across board shown novaseq instal base custom
y/i miniseq instal y/i y/i stack y/i product y/i instrument instrument instrument instrument instrument miniseq instrument y/i y/i product product y/i servic y/i array y/i y/i y/i consum instrument barclay illumina inc
spoke expect doubl today next year
expect lead signific reduct hiseq instrument
hiseq instrument collect decreas one custom transit
fleet nextseq onto novaseq instrument interestingli speak one
custom alreadi sold two novaseq anoth lab made
strateg pivot focu bioinformat cater custom buy novaseq
proprietari novaseq custom survey show major transit toward novaseq platform
custom survey expect weight averag budget increas
custom expect budget declin next year broad
rang expect growth matur center project growth
rapidli grow sequenc custom project growth one smaller
research custom cite flat budget use novaseq cost save drive offset
amount volum coverag driver sequenc growth almost everi
custom use depth everi custom expect spend least million per
year consum novaseq weight averag million
believ unlik actual attain level overal instal base
averag sinc new custom addit drag overal novaseq averag
model project million novaseq util per instrument end
result self-report back envelop math suggest
decent approxim compar net instrument add decommiss
project novaseq util would suggest custom survey
increas consum spend gb sequenc
estim custom proprietari novaseq survey increas sequenc spend
revenu grew y/i million million initi
expect prior pre-announce observ one detail
specif driver revenu miss geograph perspect growth
broadli weak quarter growth america growth emea
growth asia-pacif region revenu declin china exclud stock
order growth china would result china benefit
reproduct health oncolog test consum china stock
order
utilizationrev mmpull-through per inst per gbinstal base revsgb seq mm instal base revsgb seq mm revsgb yeary/i chang barclay illumina inc
revenu y/i growth
revenu increas y/i million total revenu
consum grew quarter adjust china stock order
consum growth would compani saw strong trend
sp flow cell quarter nextseq util within guid rang
miniseq util fell within guidanc rang miseq
util miss guidanc rang quarter novaseq util per
instrument expect grow y/i exceed instrument revenu
increas y/i servic revenu declin quarter driven
difficult comp genom england project
novaseq high throughput sequenc platform custom focus whole-
genom sequenc advantag rel legaci hiseq hiseq product
line estim instal base around hiseq hiseq instrument
compani address larg market opportun base instrument sale alon
upsid would driven market expans drive higher consum
revenu said placement cannib exist instrument consum
opportun would limit note consum cost per sampl
like go applic mean consum revenu could
actual declin per-box basi view launch make sens
revolutionari product aim drive replac cycl put rest
concern around revenu visibl near term longer term overcapac
concern like remain compani tri expand market beyond
design system larg market opportun mind note
system allow highest-throughput achiev lower sequenc cost
much lower capit commit rel hiseq hiseq
compani believ architectur novaseq platform eventu
allow achiev genom system use newli develop
company/systemlaunchedinstru costrun costrun lengthrun speedthroughputpric per gbilluminaiseq fisher life ion day all-in n/an/abgi complet genomicsrevoloc ii long nanopor barclay illumina inc
flow cell allow higher-throughput increas speed-to-result
maintain accuraci earlier system compani launch novaseq
four flow cell option prime sp four flow cell
throughout capabl tb hiseq respect
modestli reduc speed-to-result hiseq day day
novaseq price capabl run four flow cell
remind earn announc cancel novaseq
flow cell custom primarili demand novaseq
hiseq remind recent announc longer accept
hiseq order importantli focus convert exist hiseq custom
novaseq remind hiseq launch per
system januari announc launch hiseq
enhanc leverag capabl hiseq system hiseq
price reagent price per gb similarli hiseq
price provid half output lower reagent costs/fast run time
hiseq util approxim hiseq consum expect
trend downward throughout beyond note hiseq
consum revenu continu steadi declin project transit novaseq
expect signific replac cycl instrument follow
recent launch prime flow cell said compani note number
custom need finish current project upgrad
hiseq launch novaseq plan drive replac cycl
hiseq custom come year launch hiseq
sequenc whole human genom compani market product
 sell ten instrument increas throughput larg genom center
reach covet genom price system million
januari announc would sell hiseq five system
configur known hiseq hiseq allow product center
adopt high-throughput whole genom sequenc lower capit invest
 full util set-up estim sequenc
genom year compani sell hiseq system million
addit hiseq xs million thereaft sequenc cost per gb
approxim versu hiseq
nextseq launch nextseq system fill nich product
portfolio hiseq miseq instrument product flex whole
human genom sequenc target panel price per system
estim compani place nextseq global pull-through
within guid rang earn rais
nextseq pull-through guidanc rang
also launch nextseq combin microarray scan
nextseq sequenc system initi array qualifi system
cytogenet pgd applic expect enabl broad rang
applic reproduct health genet health oncolog adapt
allow lab gain access array sequenc singl capital-expenditure
miseq miseq util fell compani guid rang quarter sinc
launch miniseq encourag lower expect level
miseq cannib ultim believ market desktop
instrument minimum estim place though
could make argument market size product price
unit expect annual pull-through
miniseq/iseq launch januari miniseq compani smallest
benchtop sequenc design target sequenc applic smaller lab
cost instrument roughli pull number quarter
rang model current instal base miniseq iseq
instrument earli januari announc iseq launch
expand portfolio breadth lower-throughput end sequenc
market compani describ iseq inexpens fast easi use sequenc
iseq target address market potenti custom rang
current owner new-to- custom iseq gener million
read greater per run run-tim rang hour price
per sampl rang addit sequenc cost less
instal custom less one hour shipment iseq
began end
array revenu decreas y/i quarter million softer result
driven consum servic revenu describ
observ one compani anticip array revenu
due weaker demand environ dtc test remind provid
in-hous test servic dtc test compani notabl ancestrydna compani
also supplier dtc compani run volum in-hous partner laboratori
gener revenu consum consum
revenu grew quarter driven sequenc consum y/i
look back increas instal base instrument market consum
pull follow servic revenu revenu declin y/i
declin servic y/i microarray servic y/i
mix revenu instrument vs recur
gross margin declin y/i driven lower servic volum partial off-set
favor mix consum higher margin repres revenu
quarter y/i compani non-gaap gross margin y/i
gross margin expect y/i ebitda margin
y/i
 ex-comp increas y/i revenu sg ex-comp
decreas y/i revenu put togeth total oper
expens sg stock-bas comp increas y/i revenu
non-gaap sg revenu
non-gaap ep decreas y/i revenu grew believ
impact de-lever slower growth quarter result ebit
margin declin y/i line y/i ep growth also impact
increas compani tax rate addit ep impact dilut
helix quarter helix stake deconsolid middl
quarter ep came recent follow juli pre-announce
estim origin estim
marginadj revenu dsg barclay illumina inc
quarterli non-gaap ep y/i growth
estestestestestestincom statement growth growth growth growth growth growth y/i growth product revenu ex product revenu inc product revenu inc servic servic gross gross margin inc gross margin inc growth gener growth base sg stock base opex ebitda growth oper incom ebit growth invest debt expens pre-tax pre-tax growth incom tax non-control interest net adj net growth growth net net barclay illumina inc
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
